-+ 0.00%
-+ 0.00%
-+ 0.00%

Addex Therapeutics Reported Q2 EPS Of CHF0.08, Cash Balance Of CHF3.8M

Benzinga·09/30/2024 06:49:34
Listen to the news

Key Half Year and Q2 2024 Financial Data:

CHF' thousands Q2 24 Q2 23* Change H1 24 H1 23* Change
Income 115 632 (517) 350 1,134 (784)
R&D expenses (339) (291) (48) (584) (547) (37)
G&A expenses (675) (737) 62 (1,453) (1,351) (102)
Total operating loss (899) (396) (503) (1,687) (764) (923)
Finance result, net (27) (125) 98 26 (127) 153
Share of net loss of associates (531) - (531) (531) - (531)
Net loss from continuing operations (1,457) (521) (936) (2,192) (891) (1,301)
Net profit / (loss) from discontinued operations 14,336 (2,154) 16,490 11,983 (4,191) 16,174
Net profit / (loss) for the period 12,879 (2,675) 15,554 9,791 (5,082) 14,873
Basic net profit / (loss) per share 0.13 (0.04) 0.17 0.10 (0.08) 0.18
Diluted net profit / (loss) per share 0.08 (0.04) 0.12 0.06 (0.08) 0.14
Net increase / (decrease) in cash and cash equivalents 2,160 1,574 586 (77) 212 (289)
Cash and cash equivalents as of June 30 3,788 7,169 (3,381) 3,788 7,169 (3,381)
Shareholders' equity as of June 30 12,651 6,126 6,525 12,651 6,125 6,525